Uses of a co-crystal of psilocybin and psilocin
US12280068B1 · kind B1 · utility
0Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2024 |
| Grant date | Apr 22, 2025 |
| Priority date | — |
| Expiry date | Nov 8, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin. The disclosure further provides methods of stimulating inducing neuroplasticity, increasing BDNF levels, and/or decreasing neuroinflammation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.